Regeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regeneron Pharmaceuticals and Sanofi are conducting a Phase 2 clinical trial titled ‘A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype.’ The study aims to evaluate the effectiveness and safety of Dupilumab in treating ulcerative colitis with an eosinophilic phenotype, a condition that significantly impacts patients’ quality of life.
The intervention being tested is Dupilumab, an experimental drug administered via subcutaneous injection. The study compares Dupilumab to a placebo to assess its efficacy in reducing symptoms of ulcerative colitis.
This interventional study is designed as a randomized, double-blind, placebo-controlled parallel-group trial. Participants are randomly assigned to receive either Dupilumab or a placebo, with both participants and researchers unaware of the assignments to ensure unbiased results. The primary purpose of the study is treatment.
The study began on January 12, 2023, with an estimated completion date in August 2025. The primary completion date is not specified, but the last update was submitted on August 7, 2025, indicating ongoing progress.
The outcome of this study could significantly influence the stock performance of Regeneron Pharmaceuticals and Sanofi, as positive results may enhance investor confidence and market position. The study’s progress is crucial for stakeholders, given the competitive landscape in the pharmaceutical industry.
The study is currently recruiting, and further details can be accessed on the ClinicalTrials portal.